anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
10 asymptomatic DHCWs in the Oral Medicine clinic, Rutgers School of Dental Medicine, with no history of documented COVID-19 infection or viral exposure, were enrolled in the DHCW arm of the study. The DCHWs underwent triage that included self-reported symptoms, temperature check and obtaining a pulse oximeter reading at every study time-point (See DHCW Arm in Results Section). Weekly Rapid Antigen testing of nasal swab specimens was used to document Antigen negativity during the study (BD Veritor Plus Analyzer, BD Sciences). The DHCWs' perceptions of safety and adoption of risk mitigation behavior were interrogated. Following a baseline survey, finger-prick blood samples were collected twice two weeks apart using avolumentric absorptive microsampling with a Neoteryx Mitra cartridge device (https://www.neoteryx.com) device that allows for self-sampling by non-specialized personnel (https://doi.org/10.1101/2021.07.09.21260266). Briefly, this microsampler allows for volumentric absorption of 10-30 μl of blood depending on selected size. Following the collection, microsamplers were dried and kept within the protective cassettes at room temperature for maximum period of 2 weeks from the collection date. Each microsampler tip (20µl in the present study) was added to 200 μl VAMS extraction buffer (1x PBS (Corning) supplemented with 1% bovine serum albumin (Roche Diagnostics, Mannheim, Germany) and 0.5% Tween20 (Sigma, MO, USA) in a 1 ml deep-well 96 well plate (Greiner bio-one-780261). The plate was then covered with an adhesive seal and incubated 16 hours at 40C on a shaker at 250 rpm. The resulting eluates were heat inactivated at 560C for 60 minutes and centrifugation to collect the supernatant (eluate). Eluates were further processed for an in-house ELISA assay to detect IgM and IgG directed against the Receptor Binding Domain (RBD) of the SARS-CoV-2 Spike protein as described (https://doi.org/10.1101/2021.07.09.21260266)..
The disclosure provides a Daci loach antibacterial peptide Hepcidin-like, the amino acid sequence of which is shown in SEQ ID NO. 1. The present disclosure also provides a preparation method of the spiny loach antibacterial peptide, which comprises the following steps: (a) carrying out PCR amplification by taking the cDNA of the liver tissue of the spiny loach as a template to clone a Hepcidin gene sequence; (b) electrophoretic separation, recovering and purifying, connecting to a carrier, and converting to competent cells; (c) and connecting the plasmid with the vector to obtain the recombinant plasmid. (d) The recombinant plasmid was transformed into BL 21. (e) Inoculating the strain into LB liquid culture medium containing ampicillin for culture, and centrifuging to collect bacterial precipitate; (f) and (4) protein purification. The inventor discovers for the first time that a protein fragment in Hepcidin protein has good antibacterial activity and can be used as the basis for subsequent research and development of vaccines and related diagnostic detection kits.
Attention deficit hyperactivity disorder (ADHD) is a common developmental disorder that affects between 4% and 12% of school-aged children. Children with ADHD often show symptoms of hyperactivity, inattention, inability to sit still, trouble listening, excessive talking, and aggression. ADHD is generally not diagnosed and treated in children less than 6 years old because some symptoms of ADHD are difficult to distinguish from normal behaviors of preschool-aged children. However, some preschool children who exhibit symptoms indicative of ADHD and who have been carefully diagnosed by a health professional may benefit from early treatment to lower risk for functional impairment later in childhood. Currently, environmental changes, parent effectiveness training, and behavior therapy are the commonly used treatments for preschoolers with ADHD symptoms, but not all preschoolers respond well to such behavioral interventions. These children may benefit from medication treatment; however, the safety and effectiveness of ADHD medications in treating preschool-aged children is not well known. Extended release mixed amphetamine salts (XR-MAS), a stimulant medication, is a commonly prescribed and approved medication for treating ADHD in children 6 years and older. Further study is needed to determine how XR-MAS affects preschool-aged children with ADHD symptoms. This study will compare the safety and effectiveness of XR-MAS versus placebo in treating preschool children with ADHD.

Participation in this study will last 6 weeks. All participants will first undergo rigorous psychiatric assessments to confirm their diagnosis of ADHD. Eligible participants will then be assigned randomly to receive treatment with either XR-MAS then placebo or placebo then XR-MAS. Participants will take their assigned XR-MAS or placebo medications for 3 weeks and then cross over to the other medication for an additional 3 weeks of treatment. Rating scale scores will be collected weekly from parents and teachers to assess symptom response and measures of safety.
Dual antiplatelet therapy with aspirin and clopidogrel has become the standard care in patients with acute coronary syndrome (ACS). However, clopidogrel is being questioned for its insufficient platelet inhibition and residual platelet reactivity, especially in patients with impaired renal function. Ticagrelor, a new P2Y12 receptor antagonist, achieve faster, consistent and higher platelet inhibition than clopidogrel, which was more noticeable in patients with ACS combining chronic kidney disease(CKD). Nonetheless, the pharmacokinetic properties of ticagrelor in the patients with CKD and NSTE-ACS, to the best of the investigators' knowledge, has not been thoroughly studied. This study was designed to provide PK and PD data of ticagrelor compared with clopidogrel, in order to estimate that ticagrelor is superior to clopidogrel in getting better inhibition of platelet in patients with CKD and NSTE-ACS. The potential hypothesis is to evaluate the correlation of platelet inhibition and renal function and CYP2C19 gene type in patients treated by ticagrelor and clopidogrel. P2Y12 inhibitor naïve patients with CKD (eGFR \< 60 ml/min/1.73m2 ) and NSTE-ACS will be enrolled in this single-center, prospective, randomized, parallel study and randomly assigned in a one-to-one ratio to receive ticagrelor or clopidogrel on top of chronic aspirin treatment. The primary endpoint was the PRU by Verify Now at 30 days after loading dose.
The following adverse reactions have been identified during postapproval use of risperidone; because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency: agranulocytosis, alopecia, anaphylactic reaction, angioedema, atrial fibrillation, blood cholesterol increased, blood triglycerides increased, catatonia, diabetes mellitus, diabetic ketoacidosis in patients with impaired glucose metabolism, drug withdrawal syndrome neonatal, dysgeusia, hypoglycemia, hypothermia, ileus, inappropriate antidiuretic hormone secretion, intestinal obstruction, jaundice, mania, pancreatitis, priapism, QT prolongation, sleep apnea syndrome, somnambulism, Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), thrombocytopenia, thrombotic thrombocytopenic purpura, urinary retention, and water intoxication. In addition, the following adverse reactions have been observed during postapproval use of Risperidone for Extended-Release Injectable Suspension: cerebrovascular disorders, including cerebrovascular accidents, and diabetes mellitus aggravated.

Retinal artery occlusion after injection of Risperidone for Extended-Release Injectable Suspension has been reported during postmarketing surveillance. This has been reported in the presence of abnormal arteriovenous anastomosis.

Serious injection site reactions including abscess, cellulitis, cyst, hematoma, necrosis, nodule, and ulcer have been reported with Risperidone for Extended-Release Injectable Suspension during postmarketing surveillance. Isolated cases required surgical intervention.

Very rarely, cases of anaphylactic reaction after injection with Risperidone for Extended-Release Injectable Suspension have been reported during postmarketing experience in patients who have previously tolerated oral risperidone.

Postmarketing cases of extrapyramidal symptoms (dystonia and dyskinesia) have been reported in patients concomitantly taking methylphenidate and risperidone when there was an increase or decrease in dosage, initiation, or discontinuation of either or both medications.
INTRODUCTION: Body mass index (BMI) is often used in surgical settings to determine patients' risk of complications. In the context of gender-affirming care, BMI requirements for surgery can limit access to necessary care for larger-bodied people. There is a critical need to understand the association between BMI and postoperative outcomes for this population.
METHODS: A retrospective chart review was conducted using the first 250 consecutive gender-affirming masculinizing chest reconstructions performed between 2017 and 2021 at a large academic medical institution. The relationships between BMI, preoperative factors, and common postsurgical outcomes were assessed.
RESULTS: Average BMI at surgery was 27.5 ± 6.7 kg/m2. Increases in BMI were associated with longer drain stays, larger volume of tissue resected, higher likelihood of nipple grafts, and lower likelihood of periareolar surgery (all P < 0.0001). Simple logistic regression revealed that BMI increases were significantly related to the likelihood of experiencing dog ears in the intermediate term (P = 0.002). Multivariate logistic regression adjusted for common covariates (age, ethnicity, smoking status, asthma, autoimmune disorders, cardiovascular conditions, and mental health disorders) did not reveal any significant relationships between BMI and the likelihood of experiencing complications at any study point.
CONCLUSIONS: Masculinizing chest reconstruction is safe and satisfactory for young adult patients across the range of BMI, with significant differences in outcomes found only for esthetic complications (i.e., dog ears). Surgeons should inform patients with higher BMIs about what outcomes to expect but higher BMI should not preclude surgery access.
OBJECTIVE: To present a narrative review of fundamental information needed to manage postoperative complications in patients who have undergone genital gender-affirming surgery (GAS).
METHODS: A narrative review was performed using the following keywords: 'gender-affirming surgery', 'complications', 'emergency', 'postoperative'. Articles were included after being reviewed by two primary authors for relevance. Four clinicians with significant experience providing both primary and ongoing urological care to patients after GAS were involved in article selection and analysis.
RESULTS: The most common feminising genital GAS performed is a vaginoplasty. The main post-surgical complications seen by urologists include wound healing complications, voiding dysfunction, postoperative bleeding, vaginal stenosis, acute vaginal prolapse and graft loss, rectovaginal fistula, and urethrovaginal fistula. The most common masculinising genital GAS options include metoidioplasty and phalloplasty. Complications for these surgeries include urethral strictures, urethral fistulae, and urethral diverticula. Penile implants may also accompany phalloplasties and their complications include infection, erosion, migration, and mechanical failure.
CONCLUSION: Genital GAS is increasing, yet there are still many barriers that individuals face not only in accessing the surgeries, but in receiving follow-up care critical for optimal outcomes. Improved education and training programmes would be helpful to identify and manage postoperative complications. Broader cultural level changes are also important to ensure a safe, gender-inclusive environment for all patients.
Background: The World Health Organization reports that back pain is a major cause of disorder worldwide. It is the most common musculoskeletal disorder with limited pain, muscle tension, and stiffness, and 70-80% of all individuals experience it once in their lifetime, with higher prevalence in women than in men. This study aimed to investigate the effects of gluteal muscle strengthening exercise- based core stabilization training (GSE-based CST) on pain, function, fear-avoidance patterns, and quality of life in patients with chronic back pain. Methods: This study included 34 patients with non-specific chronic low back pain. Seventeen individuals each were included in GSE-based CST and control groups. The GSE-based CST group performed GSE and CST for 15 min, three times a week for four weeks, and the control group performed CST for 30 min a day, three times a week for four weeks. The numeric pain rating scale was used to evaluate pain before and after treatment, Roland-Morris disability questionnaire was used to evaluate function, fear-avoidance beliefs questionnaire was used to evaluate fear-avoidance patterns, and quality of life was measured using the short form-36. Results: In this study, pain, function, and fear-avoidance pattern decreased significantly in both groups (All p < 0.05). During the evaluation of quality of life, both groups showed significant increase in physical and mental factors (p < 0.05). There were significant differences in pain and quality of life (p < 0.05) between the GSE-based CST and control groups. Conclusions: Therefore, GSE-based CST can be used as a basis for effective intervention to enhance pain, function, fear-avoidance patterns, and quality of life, emphasizing the need for gluteal muscle strengthening exercises in patients with non-specific chronic back pain in the future.
The epidemiology of lung cancer related to interstitial lung disease (ILD) with or without with connective tissue disease (CTD) as well as idiopathic pulmonary fibrosis (IPF) has not been well established yet. Interstitial lung disease has a potential to develop lung cancer in the name of scar cancer. The investigators aimed to explore prevalence of lung cancer in patients with ILD with or without CTD and IPF in comparison with chronic obstructive pulmonary disorder (COPD).

The investigators will evaluate the prevalence of lung cancer associated with ILD and IPF utilizing the Korean Health Insurance Review and Assessment Service (HIRA) database, spanning the period from January 2011 to December 2011. The database (HIRA-NPS-2011-0001) was based on random sampling of outpatients from whole population. The sample cases are total 1,375,842. Among them 670,258 cases (age \> 40) were evaluated. Patients with ILDs, IPF, CTD, and COPD will be identified based on the International Classification of Disease-10 (ICD-10) diagnostic codes.
Up to 80 subjects in 4 cohorts (up to 20 subjects per cohort) will be dosed in up to 3 study periods. In each period, subjects will receive active drug or placebo with GHRH, OGTT and CRH with desmopressin (optional).
Arts-based HIV stigma intervention for two 8-week periods (16 weeks). Each intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the "problem" through finding "solutions" and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions.
The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.
The invention relates to a formula of a medicine for preventing hair loss and growing hair. The medicine is characterized by being prepared from the following medicinal materials by weight: 50-200g of fresh Chinese arborvitae twigs, 10-30g of mulberry leaves, 10-30g of tuber fleeceflower roots, 100-200 capsules of cod-liver oil, 100-200g of cystine tablets, 100-200 vitamin B6 and 400-800ml of a 60% (by volume) white spirit. A method for preparing the medicine comprises the following steps: putting the collected fresh Chinese arborvitae twigs into a clean garlic mortar, smashing, grinding the mulberry leaves and the tuber fleeceflower roots into powder, adding the powder of the mulberry leaves and the tuber fleeceflower into the white spirit, sealing to store for 7 days, and filtering to remove dregs from the white wine to obtain the medicine for later use. The cod-liver oil, the cystine tablets and the vitamin B6 can be bought directly from a drugstore. The fresh Chinese arborvitae twigs, the mulberry leaves, the tuber fleeceflower roots, the white wine, the cystine tablets, the capsules of cod-liver oil and the vitamin B6 are combined and compounded to fulfill the functions of tonifying the liver and the kidney, clearing away the lung heat, moistening dryness and growing and blacking hair. According to the use method, the medicine provided by the invention is used externally once a day and orally taken three times a day for one month in every one course of treatment.
NEW MATERIAL:A lysozyme salt of the compound of formula (M is O or S; R1-R4 are H, lower alkyl or aryl). EXAMPLE:Carboxyethylgermanium sesquioxide lysozyme salt. USE:A biological response controlling agent having interferon-inducing activity, macrophage-activation activity, antitumor activity, etc. A drug preparation having long-acting effect and high bioavailability can be produced from the agent. PREPARATION:For example, the compound of formula (e.g. car boxyethylgermanium sesquioxide) and lysozyme are made to react with each other in an aqueous solvent and the objective compound is precipitated by adding e.g. ethanol to the obtained solution.
PURPOSE: A taste modifier and foods, extracts, medicines and dental compositions containing the same are provided. The taste modifier has no toxicity, taste and smell, is prepared cheaply, and removes undesired smell from foods, extracts, medicines and dental compositions. CONSTITUTION: A taste modifier comprises paratinose-heating substance as an effective component, wherein the paratinose-heating substance is obtained by heating paratinose at 140 to 200 deg. C, preferably 150 to 180 deg. C in the presence of 10 to 30 % of water for 10 minutes to 2 hours. The taste modifier comprises 5-£(alpha-D-glucopyranosil oxy) methyl|-2-furancarboxaldehyde represented by the formula 1. The foods, extracts, medicines and dental compositions comprising the taste modifier are provided.
The present invention includes compounds, comprising a portion capable of converting a substrate, for example ethanol, to acetaldehyde and a means of directing the compounds to selected cells, and their use in therapeutic compositions and methods. The compounds may be administered with the substrate, for example ethanol, and an inhibitor of aldehyde dehydrogenase. As an example, acetaldehyde may be produced locally in tumours as a result of the presence of the enzyme alcohol dehydrogenase within the tumour targeted there by either antibody delivery systems, liposomes or gene therapy delivery systems, or any other suitable system to allow the localisation of a suitable enzymatically active component at the tumour site. When the substrate is pyruvate (i.e. the portion capable of converting a substrate to acetaldehyde is a catalytically active portion of pyruvate decarboxylase), the substrate may preferably be endogenous, i.e. present naturally in the body, particularly in or in the vicinity of the target cells.
FIELD: veterinary pharmacology. SUBSTANCE: preparation has active compounds (dioxydin and sulphalen) at amount 0.55-0.65% and 7.50-12.50% of volume, respectively, and gelatin-glycerol base - the rest. Preparation in form of pessary is administrated to cows intravaginally, intra uterine (3-8 things per one administration depending of living mass), in each 72 h up to uterine cervix closing. For prophylaxis the preparation is used once. Fitness period is 1 year. Preparation has no contraindication. Preparation is used for prophylaxis of complications at postdelivery period and for treatment of vulvitis, cervititis, vestibulo-vaginitis, acute and chronic metritis. EFFECT: enhanced effectiveness of preparation.
PURPOSE:To prepare an oral drug having high rate of absorption of the effective component, and keeping high concentration in blood for a long time, by dissolving ubidecarenone useful as a remedy for congestion, stenocardia, etc., in a fatty acid. CONSTITUTION:Ubidecarenone is dissolved in a fatty acid such as oleic acid, linoleic acid, etc., and formed to capsules, tablets, etc. for oral administration. The necessary amount of the fatty acid is to dissolve the ubidecarenone, pref. 5-60 times weight of ubidecarenone. If necessary, diluent, disintegration agent, lubricant, binder, etc. may be incorporated in the preparation. The oral drug thus obtained has largely improved absorption characteristics, durability, etc. compared to the separate administration of ubidecarenone.
PURPOSE:A cosmetic, containing soluble collagen and a derivative thereof and lecithin in combination, having improved humectant properties and feeling of use without stickiness with little change in viscosity or hardness with time. CONSTITUTION:A cosmetic containing one or two or more of soluble collagens, e.g. obtained by hydrolyzing collagen which is one of hard proteins constituting principal components of connective tissues of bones, cartilages, sinews, fish scale, etc., and preferably prepared by hydrolyzing the collagen with an acid, alkali or enzyme, and a derivative thereof and one or more of lecithins, e.g. lecithin extracted from egg yolk and soybeans. The amount of the collagens is 0.01-2wt%, particularly 0.02-1.5wt% based on the total amount of the cosmetic and the amount of the lecithins is 0.01-5wt%, preferably 0.05-3wt% based on the total amount of the cosmetic. EFFECT:Good stability and safety.
An immunogen conjugate for prodn. of antibodies against a hapten contg. an amine gp., where the conjugate is of formula (hapten-CO)p(NH)Carrier (where the hapten is coupled via an amine gp., the carrier is an immunogenic protein or polypeptide coupled directly via amine gps., and p has an av. value between 1 and the no. of available amino gps. on the carrier).